1. Introduction {#sec1-ijms-20-04730}
===============

"*United to end tuberculosis: an urgent global response to a global epidemic*" is the title of the declaration adopted by the UN General Assembly on the fight against tuberculosis (TB), which reaffirmed the commitment to end the tuberculosis epidemic globally by 2030 \[[@B1-ijms-20-04730]\]. The General Assembly acknowledged that the Millennium Development Goals \[[@B2-ijms-20-04730]\] and associated strategies helped to reverse the trend of the tuberculosis epidemic and until 2016 reduced the tuberculosis mortality by 37%. Nonetheless, the current WHO year report \[[@B3-ijms-20-04730],[@B4-ijms-20-04730]\] revealed alarming statistics showing that throughout the world about 3 TB deaths occurred and about 19 persons developed TB every minute. On the other hand, drug development against *Mycobacterium tuberculosis* (*Mt*), despite the increased occurrence of multiple drug resistant (MDR-TB) and extensively drug resistant (XDR-TB) strains, has reached a noticeable progress on inhibitor design against 2-trans enoyl-acyl carrier protein reductase (InhA), the most frequently addressed validated mycobacterial drug target. The division of the InhA substrate binding site into three structural subsites (site I, catalytic; site II, hydrophobic; site III, hydrophilic) and the determination of the catalytic residue Tyr158 conformation ('in' or 'out'), have paved the way for the improvement in structure-based design and development of novel InhA inhibitors \[[@B5-ijms-20-04730]\]. Another important observation is connected with the presence of a previously unnoticed interaction pocket formed by the side chains of Phe41 and Arg43 at the InhA active site displaying Tyr158 'out' conformation \[[@B6-ijms-20-04730]\]. Promising drug candidates, which target the isoniazid-resistant *Mt*, are direct InhA inhibitors that do not require KatG (*Mycobacterium tuberculosis* catalase-peroxidase) activation \[[@B7-ijms-20-04730]\]. Recent useful structural information involving key binding site residues identified by site-directed mutations of the InhA gene revealed that these residues (except Ser94 and Tyr158) interact with the ligand mostly through hydrophobic contacts \[[@B8-ijms-20-04730]\]. The long list of known InhA inhibitors may be divided into, on the one hand, class 1 scaffolds: triclosan derivatives (TCL) \[[@B9-ijms-20-04730]\], diphenyl ether \[[@B10-ijms-20-04730],[@B11-ijms-20-04730]\], pyrrolidine carboxamide (PCAM) \[[@B12-ijms-20-04730]\], and aryl amide derivatives \[[@B13-ijms-20-04730]\] with Tyr158 'in' conformation and typical stacking interaction with the Phe97 residue. On the other hand, class 2 scaffolds include methyl-thiazole derivatives \[[@B5-ijms-20-04730]\], pyrazoles \[[@B14-ijms-20-04730]\], benzamides \[[@B15-ijms-20-04730]\] with Tyr158 'out' conformation and interaction with the Phe41 and Arg43 pocket instead of the stacking with Phe97. The 3D-QSAR pharmacophores (PH4) for InhA inhibition are available for class 1 TCL and PCAM inhibitors only \[[@B16-ijms-20-04730],[@B17-ijms-20-04730]\] but not for the class 2 compounds. [Figure 1](#ijms-20-04730-f001){ref-type="fig"}A,B show various numbers of hydrophobic features (HYD) for the PH4 of TCL and PCAM. The third HYD feature of TCL PH4 suggests that a bulky group can fill large hydrophobic pocket (LHP, site II) delimited by residues Met155, Pro193, Ile215, Leu217, Leu218, and Trp222 as a major structural requirement for efficient InhA inhibition \[[@B18-ijms-20-04730]\]. Indeed, the best substitutions on candidates with the Triclosan scaffold direct a nonpolar group containing an ethyl linker capped by phenyl (IC~50~^exp^ = 21 nM) or pentyl group (IC~50~^exp^ = 11 nM with removal of all Cl atoms) to this LHP. The preliminary 'interaction generation' analysis of the InhA active site with no ligand bound (PDB: 4DRE, [Figure 1](#ijms-20-04730-f001){ref-type="fig"}C) revealed at least four HYD features, two of them located in the LHP. Structure--activity relationships involving interactions of 3D pharmacophore have been previously reported for HIV-1 inhibition, genetic disorders treatment, or proton pump inhibition \[[@B19-ijms-20-04730],[@B20-ijms-20-04730],[@B21-ijms-20-04730]\].

The main objective of this work was to design novel potent N-benzyl-4-((heteroaryl)methyl) benzamides (BHMBs) based on a series of 19 (training set) plus 6 (validation set) nanomolar inhibitors with observed inhibitory potencies as low as IC~50~^exp^ = 20 nM \[[@B23-ijms-20-04730]\]. Starting with in situ modification of the crystal structure of InhA-BHMB~2~ complex (PDB: 4QXM), we have elaborated a QSAR model which correlated Gibbs free energies of InhA-BHMB~x~ complex formation with the potencies IC~50~^exp^ and determined the active conformation of BHMBs bound at the active site of InhA of *Mt* (MM-PB complexation approach). Based on this active conformation we have formulated 3D QSAR pharmacophore of InhA inhibition (PH4). Large virtual library of compounds sharing the BHMB scaffold has been generated and in silico screened with the PH4. The screening yielded virtual hits that exhibited predicted inhibitory potencies IC~50~^pre^ more than 60 times lower than the most active training set compound BHMB1. Several of the identified putative inhibitors displayed favorable ADME profiles. Moreover, a series of drugs currently used in clinical practice, which include the benzamide scaffold in their molecular structure, were assessed with our new PH4 for InhA inhibition. Top five approved drugs identified by the PH4 screening exhibited predicted potencies IC~50~^pre^ ranging from 1.7 to 60 nM.

2. Results {#sec2-ijms-20-04730}
==========

2.1. Training and Validation Sets {#sec2dot1-ijms-20-04730}
---------------------------------

The training set of 19 BHMBs and validation set of another 6 analogs ([Table 1](#ijms-20-04730-t001){ref-type="table"}) were selected from a homogeneous series of InhA inhibitors with known experimentally determined inhibitory activities originating from a single laboratory \[[@B23-ijms-20-04730]\]. The whole series was obtained by variations at two positions R~1~ and R~2~ of the phenyl ring and amide group as shown in [Table 1](#ijms-20-04730-t001){ref-type="table"}. The experimental half-maximal inhibitory concentrations (20 ≤ IC~50~^exp^ ≤ 5930 nM) \[[@B23-ijms-20-04730]\] cover a sufficiently wide concentration range for building of a reliable QSAR model. The ratio between the sizes of training and validation sets remains a critical point of correct classification but is limited by the count of the set of homologous compounds available from the literature \[[@B24-ijms-20-04730]\].

2.2. QSAR Model {#sec2dot2-ijms-20-04730}
---------------

### 2.2.1. One Descriptor QSAR Models {#sec2dot2dot1-ijms-20-04730}

Each of the 19 training sets (TS) and 6 validation sets (VS) InhA-BHMBx complexes ([Table 1](#ijms-20-04730-t001){ref-type="table"}), was prepared by in situ modification of the refined template crystal structure (PDB entry code 4QXM \[[@B23-ijms-20-04730]\]) of the complex InhA-BHMB2 as described in the Methods section. Further, the relative Gibbs free energy of the InhA-BHMBx complex formation (∆∆G~com~) was computed for each of the 25 optimized enzyme--inhibitor complexes. [Table 2](#ijms-20-04730-t002){ref-type="table"} lists computed values of ∆∆G~com~ and its components as defined in Equation (7), for the TS and VS of benzamides \[[@B23-ijms-20-04730]\]. The QSAR model explained variation in the BHMBs experimental inhibitory potencies (*p*IC~50~^exp^ = −*log*~10~(IC~50~^exp^) \[[@B23-ijms-20-04730]\]) by correlating it with computed GFE ∆∆G~com~ through linear regression (Equation (8), [Table 2](#ijms-20-04730-t002){ref-type="table"}). In addition, significant correlation obtained in this QSAR relationship permitted to determine the active bound conformation of the BHMBs at the InhA binding site and enabled definition of the PH4 pharmacophore. In search for a better insight into the binding affinity of BHBMs towards *Mt*InhA, we have analyzed the enthalpy of complexation in gas phase ∆∆H~MM~ by correlating it with the *p*IC~50~^exp^. The validity of this linear correlation (for statistical data of the regression see [Table 3](#ijms-20-04730-t003){ref-type="table"}, Equation A) allowed assessment of the significance of inhibitor-enzyme interactions (∆∆H~MM~) when solvent effect and loss of entropy of the inhibitor upon binding to the enzyme were neglected. This correlation explained about 94% of the *p*IC~50~^exp^ data variation and underlined the role of the enthalpic contribution to the binding affinity of the ligand. Similarly, the more advanced descriptor, namely the GFE of the InhA-BHMBx complex formation including all components: ∆∆H~MM~, ∆∆TS~vib~ and ∆∆G~sol~, has been assessed (for statistical data see [Table 3](#ijms-20-04730-t003){ref-type="table"}, Equation B). Relatively high values of the regression coefficient R^2^, leave-one-out cross-validated regression coefficient R^2^~xv~ and Fischer F-test of the correlation suggest strong relationship between the 3D model of inhibitor binding and the observed inhibitory potencies of the BHBMs \[[@B23-ijms-20-04730]\]. Therefore, structural information derived from the 3D models of InhA-BHMBx complexes can be expected to lead to reliable prediction of InhA inhibitory potencies for new BHMBs analogs based on the QSAR model B, [Table 3](#ijms-20-04730-t003){ref-type="table"}.

The statistical data confirmed validity of the correlation Equations (A) and (B) plotted on [Figure 2](#ijms-20-04730-f002){ref-type="fig"}. The ratio *p*IC~50~^pre^/*p*IC~50~^exp^ ≅ 1 (the *p*IC~50~^pre^ values were estimated using correlation Equation B, [Table 3](#ijms-20-04730-t003){ref-type="table"}) calculated for the validation set BHMV1-6 documents the substantial predictive power of the complexation QSAR model from [Table 2](#ijms-20-04730-t002){ref-type="table"}. Thus, the regression Equation B ([Table 3](#ijms-20-04730-t003){ref-type="table"}) and computed ∆∆G~com~ GFEs can be used for prediction of inhibitory potencies IC~50~^pre^ against *Mt*InhA for novel BHMB analogs, provided they share the same binding mode as the training set benzamides BHMB1-19.

### 2.2.2. Binding Mode of BHMBs {#sec2dot2dot2-ijms-20-04730}

Structural information enzyme--inhibitor interactions retrieved from the crystal structure of InhA-BHMB1 complex \[[@B23-ijms-20-04730]\] showed that BHMBs are InhA class 2 specific inhibitors. As indicated in [Figure 3](#ijms-20-04730-f003){ref-type="fig"}, in the catalytic site I residue Tyr158 adopted the 'out' conformation \[[@B5-ijms-20-04730]\]; the pyridine moiety of the ligand (referred to as the "warhead" \[[@B6-ijms-20-04730]\]) is in π--alkyl contact with Tyr158 and nicotinamide ring and π--donor with the hydroxyl group adjacent to the ribose of NADH. The central benzene ring of the inhibitor forms a recently observed π--π stacking interaction with Phe97 \[[@B6-ijms-20-04730]\]. In the hydrophobic site II, the dihalide-substituted benzene ring sits in the hydrophobic substrate cavity, surrounded by side chains of predominantly nonpolar residues: Met103, Met98, Ile202, Leu207, Gly104, Phe149, Ala157, Tyr158, and Ile215 \[[@B6-ijms-20-04730],[@B23-ijms-20-04730]\]. In the hydrophilic site III, the inhibitor makes hydrogen bonds with the sidechain of catalytic Met98, a key interaction reported recently \[[@B6-ijms-20-04730]\]. These specific contacts were observed for the novel class of InhA inhibitors except the interaction with the "Phe41--Arg43" pocket previously unreported before Soutter et al. \[[@B6-ijms-20-04730]\] and which will be discussed later.

2.3. Interaction Energy {#sec2dot3-ijms-20-04730}
-----------------------

Other key structural information was provided by the interaction energy (IE, ΔE~int~) diagram obtained for each training set inhibitor. IE breakdown to contributions from InhA active site residue is helpful for the choice of relevant R~1~-groups (site I) and R~2~-groups (site II) which could improve the binding affinity of BHMB analogs to the *Mt*InhA and subsequently enhance the inhibitory potency. A comparative analysis of computed IE for training set BHMBs ([Figure 4](#ijms-20-04730-f004){ref-type="fig"}) divided into three classes (highest, moderate, and lowest activity) has been carried out to identify the residues for which the contribution to binding affinity could be increased. However, the comparative analysis showed about the same level of IE contributions from active site residues for all three classes of inhibitors. Therefore, no suggestions of suitable substitutions able to improve the binding affinity as we previously reported for thymine-like inhibitors of *Mt* thymidine monophosphate kinase design could be proposed \[[@B25-ijms-20-04730]\]. Since specific substitutions could not be proposed, we have adopted a combinatorial approach to novel BHMB analogs design and in silico screened a virtual library of 114921 BHMB analogs with help of the PH4 pharmacophore of InhA inhibition derived from the complexation QSAR model. As we can see from the IE analysis ([Figure 4](#ijms-20-04730-f004){ref-type="fig"}), the TS and VS benzamides \[[@B23-ijms-20-04730]\] do not show significant interaction energies with the "Phe41--Arg43" pocket.

2.4. 3D-QSAR Pharmacophore Model

### 2.4.1. InhA Active Site Pharmacophore {#sec2dot4dot1-ijms-20-04730}

The interaction generation protocol in Discovery Studio molecular modeling program \[[@B26-ijms-20-04730]\] provides the pharmacophore features of the active site of a protein. InhA predominantly displays hydrophobic features at the active site ([Figure 1](#ijms-20-04730-f001){ref-type="fig"}C) as confirmed by previously reported works \[[@B16-ijms-20-04730],[@B17-ijms-20-04730]\], the larger being the site II hydrophobic pocket that accommodates the substrate long alkyl chains. InhA substrate-competitive inhibitors design often exploits the pocket flexibility because of the high mobility of the Tyr158, Phe149 side chains and the substrate-binding loop (Thr196--Gly208) \[[@B27-ijms-20-04730]\].

### 2.4.2. Generation and Validation of 3D-QSAR Pharmacophore {#sec2dot4dot2-ijms-20-04730}

InhA inhibition 3D-QSAR pharmacophore was generated from the active conformation of 19 TS BHMB[1-19]{.smallcaps} and evaluated by 6 VS BHMV1-6 covering a large range of experimental activity (20--5930 nM) spanning more than two orders of magnitude. The generation process is divided into three main steps: (i) the constructive step, (ii) the subtractive step, and (iii) the optimization step \[[@B26-ijms-20-04730]\] as described earlier \[[@B17-ijms-20-04730]\]. During the constructive phase, BHMB1 alone was retained as the lead (since only the activity of BHMB1 fulfilled the threshold criterion, IC~50~^exp^ ≤ 2 × 20 nM), and used to generate the starting PH4 features. In the subtractive phase, compounds for which IC~50~^exp^ \> 20 × 10^3.5^ nM = 63246 nM were considered inactive. Accordingly, none of the training set BHMBx was inactive and no starting PH4 features were removed. Finally, during the optimization phase, the score of the pharmacophoric hypotheses was improved. Hypotheses were scored according to errors in activity estimates from regression and complexity via a simulated annealing approach. At the end of the optimization, the top scoring 10 unique pharmacophore hypotheses were kept, all displaying five-point features. The cost values, correlation coefficients, root-mean square deviation (RMSD) values, the pharmacophore features, and the max-fit value of the top 10 ranked hypotheses (Hypo1−Hypo10) are listed in [Table 4](#ijms-20-04730-t004){ref-type="table"}. They were selected based on significant statistical parameters, such as high correlation coefficient, low total cost, and low RMSD.

The generated pharmacophore models were then assessed for their reliability based on the calculated cost parameters ranging from 70.1 (Hypo1) to 184.7 (Hypo10). The relatively small gap between the highest and lowest cost parameter corresponds well with the homogeneity of the generated hypotheses and consistency of the TS of BHMBx. For this PH4 model, the fixed cost (45.4) is lower than the null cost (528.2) by a difference ∆ = 482.8. This difference is a major quality indicator of the PH4 predictability (∆ \> 70 corresponds to an excellent chance or a probability higher than 90% that the model represents a true correlation \[[@B26-ijms-20-04730]\]). To be statistically significant, a hypothesis has to be as close as possible to the fixed cost and as far as possible from the null cost. For the set of 10 hypotheses, the difference ∆ ≥ 343.5, which attests to the high quality of the pharmacophore model. The standard indicators such as the RMSD between the hypotheses ranged from 1.610 to 3.809, and the squared correlation coefficient (R^2^) falls to an interval from 0.97 to 0.84. The first PH4 hypothesis with the closest cost (70.1) to the fixed one (45.4) and best RMSD and R^2^ was retained for further analysis. The statistical data for the set of hypotheses (costs, RMSD, R^2^) are listed in [Table 4](#ijms-20-04730-t004){ref-type="table"}. The configuration cost (10.63 for all hypotheses) far below 17 confirms this pharmacophore as a reasonable one.

The link between the 98% significance and the number 49 scrambled runs of each hypothesis is based on the formula S = \[1 − (1 + X)/Y\] × 100, with X the total number of hypotheses having a total cost lower than the original hypothesis (Hypo 1) and Y the total number of HypoGen runs (initial + random runs): X = 0 and Y = (1 + 49), hence 98% = {1 − \[(1 + 0)/(49 + 1)\]} × 100.

The evaluation of Hypo 1 was performed first through Fischer's randomization cross-validation test. The CatScramble program was used to randomize the experimental activities of the training set. At 98% confidence level, each of the 49 scramble runs created ten valid hypotheses, using the same features and parameters as in the generation of the original 10 pharmacophore hypotheses. Among them, the cost value of Hypo1 is the lowest compared with those of the 49 randomly generated hypotheses, as we can see in [Table 4](#ijms-20-04730-t004){ref-type="table"} where the lowest cost of the 49 random runs is listed for each original hypothesis, and none of them was as predictive as the original hypotheses generated shown in [Table 4](#ijms-20-04730-t004){ref-type="table"}. Thus, there is a 98% probability that the best selected hypothesis Hypo1 represents a pharmacophore model for inhibitory activity of BHMBs with a similar level of predictive power as the complexation QSAR model, which relies on the BHMBx active conformation from 3D structures of the InhA-BHMBx complexes and computed GFE of enzyme--inhibitor binding ΔΔG~com~. Another evaluation of Hypo 1 is the mapping of the best active training set BHMB1 ([Figure 5](#ijms-20-04730-f005){ref-type="fig"}) displaying the geometry of the Hypo1 pharmacophore of InhA inhibition. The regression equation for *p*IC~50~^exp^ vs. *p*IC~50~^pre^ estimated from Hypo1: *p*IC~50~^exp^ = 1.0013 × *p*IC~50~^pre^ − 0.0085 (n = 19, R^2^ = 0.95, R~xv~^2^ = 0.93, F-test = 324.25, σ = 0.165, α \> 98 %) is also plotted on [Figure 5](#ijms-20-04730-f005){ref-type="fig"}.

We can carry out computational design and selection of new BHMB analogs with elevated inhibitory potencies against *Mt*InhA, based on a strategy using the noticeable presence of the hydrophobic features included in the best pharmacophore model at the position of R~2~ coupled with mapping of R~1~ to the aromatic ring feature and the appropriate ring substitution to the hydrophobic aliphatic feature in Hypo1 ([Figure 5](#ijms-20-04730-f005){ref-type="fig"}).

2.5. Virtual Screnning {#sec2dot5-ijms-20-04730}
----------------------

In silico screening of a virtual (combinatorial) library can lead to hit identification as it was shown in our previous works on inhibitors design \[[@B17-ijms-20-04730],[@B28-ijms-20-04730],[@B29-ijms-20-04730]\].

### 2.5.1. Virtual Library {#sec2dot5dot1-ijms-20-04730}

An initial virtual library (VL) was generated by substitutions at positions for R~1~ and R~2~ (see [Table 5](#ijms-20-04730-t005){ref-type="table"}) on the benzamide scaffold. During the virtual library enumeration, all 339 R-groups listed in [Table 5](#ijms-20-04730-t005){ref-type="table"} were attached to in positions R~1~ and R~2~ of the BHMB scaffold to form a combinatorial library of the size: R~1~ × R~2~ = 339 × 339 = 114,921 analogs. This initial diversity library was generated from building blocks (chemicals) listed in the databases of available chemicals \[[@B30-ijms-20-04730]\]. To design a more focused library of a reduced size and increased content of drug-like molecules, we have introduced a set of filters and penalties such as the Lipinski rule-of-five \[[@B31-ijms-20-04730]\], which helped to select a smaller number of suitable BHMBs that could be submitted to in silico screening. This focusing has reduced the size of the initial library to 73,565 analogs, 64% of its original number size.

### 2.5.2. In Silico Screening of Library of BHMBs {#sec2dot5dot2-ijms-20-04730}

The focused library of 73,565 analogs was further screened for molecular structures matching the 3D-QSAR PH4 pharmacophore model Hypo1 of InhA inhibition. 238 BHMBs mapped to at least 2 pharmacophoric features, 90 of which mapped to at least 4 features of the pharmacophore. These best fitting analogs (PH4 hits) then underwent complexation QSAR model screening. The computed GFE of InhA-BHMBx complex formation, their components, and predicted half-maximal inhibitory concentrations IC~50~^pre^ calculated from the correlation Equation B ([Table 3](#ijms-20-04730-t003){ref-type="table"}) are listed in [Table 6](#ijms-20-04730-t006){ref-type="table"}.

2.6. Novel BHMB Analogs {#sec2dot6-ijms-20-04730}
-----------------------

The design of virtual library of novel analogs was guided by structural information retrieved from the BHMBx active conformation and was used for the selection of appropriate substituents (R~1~- and R~2~-groups). In order to identify which substituents lead to new inhibitor candidates with the highest predicted potencies towards the InhA of *Mt*, we have prepared histograms of the frequency of occurrence of R~1~- and R~2~-groups among the 90 best fit PH4 hits ([Figure 6](#ijms-20-04730-f006){ref-type="fig"}). The histograms show that the R~1~ groups 79, 310, and 318 were represented with the highest frequency of occurrence (5) among the 90 BHMB hits. The R~2~-groups most frequently represented in this subset are 282 (10) and 232, 233 (6) and 99, 215 and 235 (5). The top ten scoring virtual hits, namely, analogs are 79-92 (IC~50~^pre^ = 33 pM), 79-339 (39 pM), 79-338 (47 pM), 41-93 (52 pM), 234-99 (90 pM), 238-25 (90 pM), 122-92 (100 pM), 220-99 (110 pM), 310-99 (110 pM), and 166-92 (150 pM). They include the following substituents at R~1~ position: 79: 3-Br-2-(thiazol-2-yl)Pr (3), 41: Thiophen-2-ylMe (1), 234: (2,3-diFC~5~H~7~- 2,4-dien-1-yl)(mercapto-amino)Me (1), 238: FNH(3-FC~5~H~7~-2,4-dien-1-yl)Me (1), 122: 2-(F~3~C)Pyri- din-3-yl (1), 220: 2,3-diBr C~5~H~7~-2,4-diene-carbonyl (1), 310: 3-F-1-H-pyrazol-1-yl (1), 166: 4-(3-NH~2~-1- H-pyrazol-1-yl)Ph (1), or at R~2~ position: 92: 4-HO-Hexyl (3), 339: 2-(thiazol-2-yl)butyl (1), 338: 2-(thiazol-2-yl)pentyl (1), 93: 5-NH~2~-6-Br Hexyl (1), 99: 6-NH~2~Octyl (3), 25: 6-MeOctyl (1). Due to amino acid composition of the larger hydrophobic pocket, the R~2~-groups display preferences for larger aliphatic building blocks from butyl to octyl \[[@B5-ijms-20-04730]\].

The substitutions in R~1~ and R~2~ positions of BHMBs led to an overall increase of affinity of InhA binding as exemplified by the inhibitory potencies of majority of new designed analogs. The best designed benzamide BHMB 79--92 displays predicted half-minimal inhibitory concentration of IC~50~^pre^ = 33 pM that is about 61 times lower than that of the most active compound of the TS, namely the BHMB1 with IC~50~^exp^ = 20 nM, [Figure 7](#ijms-20-04730-f007){ref-type="fig"} and [Figure 8](#ijms-20-04730-f008){ref-type="fig"}.

2.7. Pharmacokinetic Profile of Novel BHMB Analogs {#sec2dot7-ijms-20-04730}
--------------------------------------------------

The pharmacokinetic profile of InhA inhibitors remains an important issue \[[@B7-ijms-20-04730]\]. The best designed triclosan derivative with very low oral bioavailability due to its poor water solubility and rapid phase II metabolism has to be optimized for a possible use as antituberculotic and eventually antimalarial in case of high affinity toward *Pf*EACP \[[@B32-ijms-20-04730]\]. Among the ADME-related properties displayed in [Table 7](#ijms-20-04730-t007){ref-type="table"}, such as octanol-water partitioning coefficient; aqueous solubility; blood-brain partition coefficient; Caco-2 cell permeability; serum protein binding; number of likely metabolic reactions; and another eighteen descriptors related to absorption, distribution, metabolism, and excretion (ADME) of the new analogs, were computed by the QikProp program \[[@B33-ijms-20-04730]\] based on the method of Jorgensen \[[@B34-ijms-20-04730],[@B35-ijms-20-04730]\]. Experimental data from more than 710 compounds including about 500 drugs and related heterocycles were used to produce regression equations correlating experimental and computed descriptors, resulting in an accurate prediction of pharmacokinetic properties of molecules. In line with the observed unfavorable pharmacokinetic exposure for the best active triclosan derivative, the predicted oral bioavailability of novel BHMB analogs ranges from 86% to 100%. Since a value greater than 80% is considered good, ten analogs among the best predicted 14 display a human oral absorption in gastrointestinal tract (HOA) of 100%. Drug likeness (\#stars)---the number of property descriptors that fall outside the range of optimal values determined for 95% of known drugs out of 24 selected descriptors computed by the QikProp---was used as an additional ADME-related compound selection criterion. The values for the best active designed BHMBs are compared with those computed for drugs used for treatment of tuberculosis or currently undergoing clinical trials ([Table 7](#ijms-20-04730-t007){ref-type="table"}). Our best designed analogs all display \#stars equal to zero, meaning that the optimal value range of none of the drug-likeness descriptors was violated. Thus the designed BHMBs display a favorable pharmacokinetic profile.

2.8. Predicted InhA Inhibition Potency for Current Drugs Bearing Benzamide Scaffold {#sec2dot8-ijms-20-04730}
-----------------------------------------------------------------------------------

Since the benzamide scaffold has been analyzed in this study, drugs currently used in the clinical practice sharing this scaffold are worth evaluating with the help of our 3D-QSAR generated PH4 pharmacophore. The list of 24 compounds given in [Table 8](#ijms-20-04730-t008){ref-type="table"} is mostly indicated for treatment of neural disorders and cancers \[[@B36-ijms-20-04730]\]. As we can see on [Figure 9](#ijms-20-04730-f009){ref-type="fig"}, the mapping of the five most potent predicted *Mt*InhA inhibitors to PH4 pharmacophore sheds light on their affinity towards the enzyme and suggests their experimental evaluation as antituberculotics as they predominantly occupy the large hydrophobic pocket. The best predicted, Sultopride (IC~50~^pre^ = 1.7 nM) is an approved drug, used in Japan, Hong Kong, and Europe for treatment of schizophrenia \[[@B36-ijms-20-04730]\].

3. Discussions {#sec3-ijms-20-04730}
==============

3.1. Binding Mode of BHMBs {#sec3dot1-ijms-20-04730}
--------------------------

To date, the most comprehensive study on InhA inhibition has been reported by Soutter et al. \[[@B6-ijms-20-04730]\]. An important output of their DNA-encoded screening is the novel binding mode of inhibitors at the *Mt*InhA active site, where the ligand, in addition to the typical stacking contact with Phe97 reaches a pocket surrounded by Phe41 and Arg43 side chains. This results in either a π--cation or a conventional hydrogen-bond contact. According to our analysis of the InhA-BHMBx complexes of most potent inhibitors, this interaction plays a key role in the significant improvement of predicted inhibitory potencies of novel benzamides. The enzyme--inhibitor interaction energy (E~int~) breakdown to InhA active site residues contribution of best designed BHMB analogs ([Figure 10](#ijms-20-04730-f010){ref-type="fig"}) shows that in contrast to the TS and VS inhibitors \[[@B23-ijms-20-04730]\] ([Figure 4](#ijms-20-04730-f004){ref-type="fig"}), while the contribution of Phe97 to E~int~ is almost the same, the impact of interaction with polar Arg43 increased by at least 4 kcal·mol^−1^. Surprisingly, the novel benzamide inhibitors display noticeable interaction with Phe97 and Arg43, suggesting that their length, which is comparable to that of TS BHMBs, is sufficient for concomitant interactions. Recently, site exclusion was observed for the ligands in complex with InhA (a pyrrolidine core and three substituents: benzoyl and 1-t-butoxy ethyl groups directly connected to the pyrrolidine core and a pyrazole benzaldehyde connected via the t-butoxy ethyl) benzoyl π--π stacks Phe97, methyl amide HB with Arg43), (PDB: 5G0W) \[[@B6-ijms-20-04730]\]. As displayed in [Figure 10](#ijms-20-04730-f010){ref-type="fig"}, distance between the benzamide carbonyl oxygen and the Arg43 sidechain warhead carbon atom is relatively high for the training set compounds (7.5--9.5 Å). Interestingly, the plot of this distance vs. inhibitory activity *p*IC~50~^exp^ displays a correlation. This distance seems to be one of the key determinants for binding affinity for the class 2 InhA direct inhibitors instead of the existence of a HB. This structural specificity that emerged during the PH4 screening of the virtual library of benzamide analogs led to identification of new hits, the best of which are capable of forming a HB with the Arg43 residue.

3.2. PH4-Based Screening of Approved Drugs Containing Benzamide Scaffold {#sec3dot2-ijms-20-04730}
------------------------------------------------------------------------

A library of 24 benzamide scaffold drugs from DrugBank \[[@B36-ijms-20-04730]\] was screened with the class 2 InhA inhibition PH4. These drugs are mostly dedicated to a variety of neurological and psychiatric disorders or nausea and vomiting treatment. The top five best PH4 hits have been evaluated also with the complexation QSAR model Equation B, [Table 3](#ijms-20-04730-t003){ref-type="table"}, to predict their antituberculotic IC~50~^pre^ towards the *Mt*InhA: Sultopride (IC~50~^pre^ = 1.7 nM), Diethyltoluamide (9 nM), Tricalopride (10 nM), Veralipride (23 nM) and Remoxipride (60 nM). Their mapping to the pharmacophore features is displayed in [Figure 9](#ijms-20-04730-f009){ref-type="fig"}. Therefore, experimental testing of these five approved drugs for *Mt*InhA inhibition and perhaps also for antibacterial effect against the *Mt* would be worthwhile.

4. Materials and Methods {#sec4-ijms-20-04730}
========================

4.1. Training and Validation Sets {#sec4dot1-ijms-20-04730}
---------------------------------

Chemical structures and biological activities (IC~50~^exp^) of training and validation sets of *N*-benzyl-4-((heteroaryl)methyl) benzamides inhibitors of InhA used in this study were taken from literature \[[@B23-ijms-20-04730]\]. The potencies of these compounds cover a sufficiently broad range of half-maximal inhibitory concentrations (20 ≤ IC~50~^exp^ ≤ 5930 nM) to allow construction of a QSAR model. The training set (TS) containing 19 BHMB inhibitors and the validation set (VS) including 6 BHMBs were taken from the ref. \[[@B23-ijms-20-04730]\].

4.2. Model Building {#sec4dot2-ijms-20-04730}
-------------------

Three dimensional (3D) molecular models of enzyme--inhibitor (E-I) complexes *Mt*InhA-BHMBx, free enzyme InhA and free inhibitors BHMBx were prepared from high-resolution (2.2 Å) crystal structure of a reference complex containing the training set compound *N*-(2-chloro-4-fluorobenzyl)-4-((3,5-dimethyl-1-*H*-pyrazol-1-yl)methyl)benzamide (BHMB2, [Table 1](#ijms-20-04730-t001){ref-type="table"}) bound to the mycobacterial InhA (Protein Data Bank \[[@B37-ijms-20-04730]\] entry code 4QXM \[[@B23-ijms-20-04730]\]) using Insight-II molecular modeling program \[[@B38-ijms-20-04730]\].

The structures of InhA and the E-I complexes were considered to be at pH of 7 with neutral N- and C-terminal residues and all protonizable and ionizable residues charged. No crystallographic water molecules were included in the model. The inhibitors were built into the reference structure 4QXM \[[@B23-ijms-20-04730]\] by in situ replacing of derivatized groups in the molecular scaffold of the template inhibitor BHMB2. An exhaustive conformational search over all rotatable bonds of the replacing function groups coupled with a careful gradual energy-minimization of the modified inhibitor and active site residues of the InhA located in the vicinity of the inhibitor (within 5 Å distance) was employed to identify low-energy bound conformations of the modified inhibitor. The resulting low-energy structures of the E-I complexes were then carefully refined by minimization of the whole complex. This procedure has been successfully used for model building of viral, bacterial, and protozoal enzyme--inhibitor complexes and design of peptidomimetic, hydroxynaphthoic, thymidine, triclosan, pyrrolidine carboxamide, nitriles, and chalcone-based inhibitors \[[@B16-ijms-20-04730],[@B17-ijms-20-04730],[@B29-ijms-20-04730],[@B39-ijms-20-04730],[@B40-ijms-20-04730],[@B41-ijms-20-04730],[@B42-ijms-20-04730],[@B43-ijms-20-04730],[@B44-ijms-20-04730],[@B45-ijms-20-04730],[@B46-ijms-20-04730],[@B47-ijms-20-04730]\].

4.3. Molecular Mechanics {#sec4dot3-ijms-20-04730}
------------------------

Modeling of inhibitors, InhA, and E-I complexes was carried out by molecular mechanics using CFF91 force field \[[@B48-ijms-20-04730]\] as described earlier \[[@B17-ijms-20-04730]\].

4.4. Conformational Search {#sec4dot4-ijms-20-04730}
--------------------------

Free inhibitor conformations were derived from their bound conformations in the E-I complexes by gradual relaxation to the nearest local energy minimum as described earlier \[[@B17-ijms-20-04730]\].

4.5. Solvation Gibbs Free Energies {#sec4dot5-ijms-20-04730}
----------------------------------

The electrostatic component of solvation Gibbs free energy (GFE) that includes also the effects of ionic strength via solving nonlinear Poisson--Boltzmann equation \[[@B49-ijms-20-04730],[@B50-ijms-20-04730]\] was computed by the DelPhi module in Discovery Studio \[[@B26-ijms-20-04730]\] as described earlier \[[@B17-ijms-20-04730]\].

4.6. Calculation of Binding Affinity and QSAR Model {#sec4dot6-ijms-20-04730}
---------------------------------------------------

The calculation of binding affinity expressed as complexation GFE has been described fully earlier \[[@B17-ijms-20-04730]\].

4.7. Interaction Energy {#sec4dot7-ijms-20-04730}
-----------------------

The calculation of MM interaction energy (E~int~) between enzyme residues and the inhibitor CFF91 force field \[[@B48-ijms-20-04730]\] was performed as described earlier \[[@B17-ijms-20-04730]\].

4.8. Pharmacophore Generation {#sec4dot8-ijms-20-04730}
-----------------------------

Bound conformations of inhibitors taken from the models of E-I complexes were used for constructing of 3D-QSAR pharmacophore (PH4) by means of Catalyst HypoGen algorithm \[[@B51-ijms-20-04730]\] implemented in Discovery Studio \[[@B26-ijms-20-04730]\] as described earlier \[[@B17-ijms-20-04730]\].

4.9. ADME Properties {#sec4dot9-ijms-20-04730}
--------------------

The pharmacokinetics profile of BHMBs were computed by the QikProp program \[[@B33-ijms-20-04730]\] as described earlier \[[@B17-ijms-20-04730]\].

4.10. Virtual Library Generation {#sec4dot10-ijms-20-04730}
--------------------------------

The virtual library generation was performed as described earlier \[[@B17-ijms-20-04730]\].

4.11. ADME-Based Library Searching {#sec4dot11-ijms-20-04730}
----------------------------------

The drug-likeness selection criterion served to focus the initial virtual library as described earlier \[[@B17-ijms-20-04730]\].

4.12. Pharmacophore-Based Library Searching {#sec4dot12-ijms-20-04730}
-------------------------------------------

The pharmacophore model (PH4) described in [Section 4.8](#sec4dot8-ijms-20-04730){ref-type="sec"} and derived from the bound conformations of BHMBs at the active site of InhA served as library searching tool as described earlier \[[@B17-ijms-20-04730]\].

4.13. Inhibitory Potency Prediction {#sec4dot13-ijms-20-04730}
-----------------------------------

The conformer with the best mapping on the PH4 pharmacophore in each cluster of the focused library subset was used for ΔΔG~com~ calculation and IC~50~^pre^ estimation (virtual screening) by the complexation QSAR model as described earlier \[[@B17-ijms-20-04730]\].

5. Conclusions {#sec5-ijms-20-04730}
==============

In this work novel class 2 InhA direct inhibitors with benzamide scaffold have been designed to reach the picomolar inhibitory concentration range of the predicted IC~50~^pre^ ([Table 6](#ijms-20-04730-t006){ref-type="table"}, [Figure 8](#ijms-20-04730-f008){ref-type="fig"}). Even though these predicted inhibitory potencies may be somewhat too optimistic, they suggest that benzamide-type *Mt*InhA inhibitors more potent than the known TS and VS analogs \[[@B23-ijms-20-04730]\] may exist. Our QSAR model provided bound InhA inhibitor conformation, from which the enzyme--inhibitor interaction energy breakdown to active site residue contribution clearly revealed structural determinants needed for binding improvement involving the favorable contacts in the three active site subsites (I, II, and III) including combination of π--π stacking with Phe97 and the HB contacts with Arg43. The derived 3D QSAR pharmacophores identified during chemical space exploration around R~1~ and R~2~ positions novel BHMBs analogs with predicted picomolar *Mt*InhA inhibitory potencies 79--92 (IC~50~^pre^ = 33 pM), 79--39 (39 pM) and 79--338 (47 pM) all display also favorable pharmacokinetic profiles compared to current antituberculotics. We believe that they are worth synthesizing and evaluating.

Moreover, current drugs sharing the benzamide scaffold have been in silico evaluated and the top five predicted drugs, Sultopride (IC~50~^pre^ = 1.7 nM), Diethyltoluamide (9 nM), Tricalopride (10 nM), Veralipride (23 nM), and Remoxipride (60 nM) are also suggested for biological evaluation as potential antituberculotics.
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![(**A**) 3D-QSAR pharmacophore model (PH4) for triclosan (TCL) derivatives displaying 3 HYD (cyan) features and the mapping of the most active analog synthesized (IC~50~ = 21 nM \[[@B16-ijms-20-04730]\], PDB: 3FNH \[[@B21-ijms-20-04730]\], five key interactions with InhA: HB---Tyr158, π--π---NAD and hydrophobic contacts). (**B**) PH4 for pyrrolidine carboxamide (PCAM) derivatives displaying 2 HYD (light blue) and the mapping of the most active derivative synthesized (IC~50~ = 390 nM \[[@B17-ijms-20-04730]\], PDB: 4U0J \[[@B12-ijms-20-04730]\], main interactions with InhA: HB---Tyr158, HB---NAD). (**C**) PH4 for the active site of InhA, depicted in ribbon, (PDB: 4DRE \[[@B22-ijms-20-04730]\]) with one acceptor in green color, one donor in purple color, and 4 HYD features (cyan), for clarity the acceptor and donor spheres were removed. The LHP is enclosed by 2 residues in yellow color and labeled in green surrounding two HYDs.](ijms-20-04730-g001){#ijms-20-04730-f001}

![(Left) plot of correlation equation between pIC~50~^exp^ and relative enthalpic contribution to the GFE (Equation (6)) ∆∆H~MM~ \[kcal⋅mol^−1^\]. (Right) similar plot for relative complexation Gibbs free energies of the InhA-BHMBx complex formation ∆∆G~com~ \[kcal⋅mol^−1^\] of the training set \[[@B23-ijms-20-04730]\]. The validation set data points are shown in red color.](ijms-20-04730-g002){#ijms-20-04730-f002}

![(Left) 2D schematic interaction diagram of the most potent inhibitor BHMB1 \[[@B23-ijms-20-04730]\] at the active site of InhA of *Mt*. (Right) 3D structure of the InhA active site with bound inhibitor BHMB1. (Bottom) Hydrophobic surface of the active site of InhA showing conventional hydrogen bonds (green) and alkyl group hydrophobic contacts (pink). Surface coloring legend: red = hydrophobic, blue = hydrophilic and white = intermediate.](ijms-20-04730-g003){#ijms-20-04730-f003}

![Mechanics intermolecular interaction energy E~int~ breakdown to residue contributions in \[kcal.mol^−1^\]: (**A**) the most active inhibitors BHMB1-7, (**B**) moderately active inhibitors BHMB8-13, (**C**) less active inhibitors BHMB14-19, [Table 2](#ijms-20-04730-t002){ref-type="table"} \[[@B23-ijms-20-04730]\].](ijms-20-04730-g004){#ijms-20-04730-f004}

###### 

Features (**A**) coordinates of centers, (**B**) angles between centers of pharmacophoric features, (**C**) distances between centers, (**D**) mapping of pharmacophore of InhA inhibitor with the most potent molecule BHMB1. The R~1~ position in the BHMBs of TS compounds is occupied by benzene ring (except BHMB8), therefore the second HYD expected from the InhA active site PH4 ([Figure 1](#ijms-20-04730-f001){ref-type="fig"}C) is replaced by Ar feature in BHMBs PH4. Feature legend: HYDA = Hydrophobic Aliphatic (blue), HYD = Hydrophobic (cyan), Ar = Ring aromatic (orange), HBA = Hydrogen bond Acceptor (green). (**E**) correlation plot of experimental vs. predicted inhibitory activity (open circles correspond to TS, red dots to VS).

![](ijms-20-04730-g005a)

![](ijms-20-04730-g005b)

![Histograms of frequency of occurrence of individual R-groups in the 90 best selected analogs mapping to four features of the PH4 pharmacophore hypothesis Hypo1 (for the structures of the fragments see [Table 5](#ijms-20-04730-t005){ref-type="table"}); R~1~ = -3-Br-2-(thiazol-2-yl)propyl (79); -3-F-1H-pyrazol-1-yl (310); -5-Et-1H- pyrazol-1-yl (318) and R~2~ = -(3-F-cyclopenta-2,4-dien-1-yl)(MeAmino)Me (232); -(2-F-cyclopenta-2, 4-dien-1-yl)(MeAmino)Me (233) and -Bz-2-Me (282).](ijms-20-04730-g006){#ijms-20-04730-f006}

![(**A**) Close up of virtual hit 79--92, the most active designed BHMB analog (IC~50~^pre^ = 33 pM) at the active site of InhA. Interacting residues are colored yellow, and NADH is not shown for clarity. (**B**) Mapping of the BHMB 79--92 to InhA inhibition pharmacophore. (**C**) 2D schematic interaction diagram of the BHMB 79--92 at the active site of *Mt*InhA. (**D**) 2D schematic interaction diagram of the analog BHMB 79--339 (IC~50~^pre^ = 39 pM) at the active site of *Mt*InhA. (**E**) 2D schematic interaction diagram of the ligand ((2S,4S)-N-methyl-4-\[\[(2S,3R)-3-\[(2-methylpropan-2-yl)oxy\]-2-\[\[4-(pyrazol-1- ylmethyl)phenyl\]carbonylamino\]butanoyl\]amino\]-1-(phenylcarbonyl)pyrrolidine-2-carboxamide) in complex with *Mt*InhA (PDB: 5G0W) displaying the HB contact with Arg43 as reported in \[[@B6-ijms-20-04730]\].](ijms-20-04730-g007){#ijms-20-04730-f007}

![Surface of the active site of *Mt*InhA with bound 5 best active designed BHMB analogs. The binding site surface is colored according to residue hydrophobicity: red = hydrophobic, blue = hydrophilic, and white = intermediate.](ijms-20-04730-g008){#ijms-20-04730-f008}

![Mapping of the benzamide drugs currently used in clinical practice to the InhA inhibition pharmacophore. Feature legend: HYDA = Hydrophobic Aliphatic (blue), HYD = Hydrophobic (cyan), Ar = Ring aromatic (orange), HBA = Hydrogen bond Acceptor (green). Only the top five predicted IC~50~^pre^ are displayed.](ijms-20-04730-g009){#ijms-20-04730-f009}

###### 

Molecular mechanics inter-molecular interaction energy E~int~ break-down to active site residue contributions in \[kcal.mol^−1^\]: (**A**) designed best five novel BHMB analogs (the color coding refers to ligands given in the legend), (**B**) correlation between *p*IC~50~^exp^ and distance from the benzamide carbonyl oxygen to the Arg43 warhead carbon atom (7.5--9.5 Å).

![](ijms-20-04730-g010a)

![](ijms-20-04730-g010b)

ijms-20-04730-t001_Table 1

###### 

Set (BHBM1-19) and validation set (BHBV1-6) of InhA inhibitors \[[@B23-ijms-20-04730]\] used in the preparation of QSAR models of inhibitor binding. The R~1~ and R~2~ groups are numbered in the first part of the Table as \#R ≡ group index.

![](ijms-20-04730-i001)

  -------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- -----------------------------
  **\#R**              **1**                         **2**                         **3**                         **4**                         **5**                         **6**                         **7**                         **8**
  R group              ![](ijms-20-04730-i002.jpg)   ![](ijms-20-04730-i003.jpg)   ![](ijms-20-04730-i004.jpg)   ![](ijms-20-04730-i005.jpg)   ![](ijms-20-04730-i006.jpg)   ![](ijms-20-04730-i007.jpg)   ![](ijms-20-04730-i008.jpg)   ![](ijms-20-04730-i009.jpg)
  **\#R**              **9**                         **10**                        **11**                        **12**                        **13**                        **14**                        **15**                        **16**
  R group              ![](ijms-20-04730-i010.jpg)   ![](ijms-20-04730-i011.jpg)   ![](ijms-20-04730-i012.jpg)   ![](ijms-20-04730-i013.jpg)   ![](ijms-20-04730-i014.jpg)   ![](ijms-20-04730-i015.jpg)   ![](ijms-20-04730-i016.jpg)   ![](ijms-20-04730-i017.jpg)
  **\#R**              **17**                        **18**                        **19**                        **20**                        **21**                        **22**                        **23**                        **24**
  R group              ![](ijms-20-04730-i018.jpg)   ![](ijms-20-04730-i019.jpg)   ![](ijms-20-04730-i020.jpg)   ![](ijms-20-04730-i021.jpg)   ![](ijms-20-04730-i022.jpg)   ![](ijms-20-04730-i023.jpg)   ![](ijms-20-04730-i024.jpg)   ![](ijms-20-04730-i025.jpg)
  **\#R**              **25**                        **26**                                                                                                                                                                              
  R group              ![](ijms-20-04730-i026.jpg)   ![](ijms-20-04730-i027.jpg)                                                                                                                                                         
  **Training Set**     BHMB1                         BHMB2                         BHMB3                         BHMB4                         BHMB5                         BHMB6                         BHMB7                         BHMB8
  **\#R~1~--\#R~2~**   8--17                         8--19                         **8**--14                     8--15                         12--19                        13--19                        8--26                         18--19
  IC~50~^exp^ (nM)     20                            50                            50                            60                            80                            90                            90                            120
  **Training Set**     BHMB9                         BHMB10                        BHMB11                        BHMB12                        BHMB13                        BHMB14                        BHMB15                        BHMB16
  **\#R~1~--\#R~2~**   10--19                        8--16                         9--19                         8--22                         3--19                         8--25                         6--19                         5--19
  IC~50~^exp^ (nM)     250                           260                           350                           500                           540                           1400                          1580                          1580
  **Training Set**     BHMB17                        BHMB18                        BHMB19                                                                                                                                                
  **\#R~1~--\#R~2~**   4--19                         7--19                         1--19                                                                                                                                                 
  IC~50~^exp^ (nM)     2510                          3100                          5930                                                                                                                                                  
  **Validation Set**   BHMV1                         BHMV2                         BHMV3                         BHMV4                         BHMV5                         BHMV6                                                       
  **\#R~1~--\#R~2~**   8--24                         21--19                        8--20                         2--19                         11--19                        8--23                                                       
  IC~50~^exp^ (nM)     60                            90                            320                           1260                          1580                          3250                                                        
  -------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- -----------------------------

ijms-20-04730-t002_Table 2

###### 

Gibbs free energy (binding affinity) and its components for the training set of InhA inhibitors BHMB1-19 and validation set inhibitors BHMV1-6 \[[@B23-ijms-20-04730]\].

  ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ----------------- --------------------------------------
  **Training Set ^a^**   **M~w~^b^**            **∆∆H~MM~^c^**         **∆∆G~sol~^d^**        **ΔΔTS~vib~^e^**       **∆∆G~com~^f^**   **IC~50~^exp\ g^**
  **\[g⋅mol^−1^\]**      **\[kcal⋅mol^−1^\]**   **\[kcal⋅mol^−1^\]**   **\[kcal⋅mol^−1^\]**   **\[kcal⋅mol^−1^\]**   **\[nM\]**        
  BHMB1                  385                    0                      0                      0                      0                 20
  BHMB2                  372                    3.14                   −1.75                  −0.51                  1.90              50
  BHMB3                  369                    2.99                   −0.56                  −0.33                  2.76              50
  BHMB4                  387                    3.01                   −3.09                  −2.50                  2.41              60
  BHMB5                  487                    4.31                   −5.38                  −3.96                  2.89              80
  BHMB6                  488                    4.70                   −1.02                  −0.30                  3.98              90
  BHMB7                  377                    4.24                   −3.22                  −3.45                  4.47              90
  BHMB8                  391                    4.66                   −0.01                  −0.46                  5.11              120
  BHMB9                  405                    4.77                   0.64                   0.18                   5.23              250
  BHMB10                 401                    4.63                   0.33                   −0.62                  5.58              260
  BHMB11                 369                    6.31                   1.59                   1.58                   6.32              350
  BHMB12                 358                    7.61                   −1.80                  −1.63                  7.45              500
  BHMB13                 398                    7.06                   0.29                   0.65                   6.70              540
  BHMB14                 389                    7.62                   −1.31                  −2.20                  8.51              1400
  BHMB15                 398                    8.81                   0.77                   1.00                   8.57              1580
  BHMB16                 354                    8.26                   1.50                   1.04                   8.72              1580
  BHMB17                 364                    8.54                   2.95                   1.94                   9.55              2510
  BHMB18                 337                    9.26                   1.80                   2.01                   9.05              3100
  BHMB19                 319                    11.72                  1.81                   2.84                   10.69             5930
  **Validation Set**     **M~w~^b^**            **∆∆H~MM~^c^**         **∆∆G~sol~^d^**        **ΔΔTS~vib~^e^**       **∆∆G~com~^f^**   ***p*IC~50~^pre^/*p*IC~50~^exp\ h^**
  **\[g⋅mol^−1^\]**      **\[kcal⋅mol^−1^\]**   **\[kcal⋅mol^−1^\]**   **\[kcal⋅mol^−1^\]**   **\[kcal⋅mol^−1^\]**                     
  BHMV1                  375                    2.41                   −2.49                  −2.95                  2.87              0.99
  BHMV2                  416                    4.58                   0.32                   1.45                   3.44              1.00
  BHMV3                  386                    4.61                   4.53                   2.47                   6.67              0.97
  BHMV4                  354                    8.63                   1.49                   2.12                   8.01              1.01
  BHMV5                  377                    8.47                   0.47                   0.77                   8.17              1.02
  BHMV6                  361                    8.20                   0.48                   −2.62                  11.29             0.95
  ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ----------------- --------------------------------------

^a^ for the chemical structures of the training set of inhibitors see [Table 1](#ijms-20-04730-t001){ref-type="table"}; ^b^ M~w~ is the molar mass of inhibitors; ^c^ ΔΔH~MM~ is the relative enthalpic contribution to the GFE change related to E-I complex formation derived by MM; ΔΔH~MM~ ≈ \[E~MM~{E-I~x~} − E~MM~{I~x~}\] − \[E~MM~{E-I~ref~} − E~MM~{I~ref~}\], I~ref~ is the reference inhibitor BHMB1; ^d^ ΔΔG~sol~ is the relative solvent effect contribution to the GFE change of E-I complex formation: ΔΔG~sol~ = \[G~sol~{E-I~x~} − G~sol~{I~x~}\] − \[G~sol~{E-I~ref~} − G~sol~{I~ref~}\]; ^e^ −ΔΔTS~vib~ is the relative entropic contribution of inhibitor I~x~ to the GFE of E-I~x~ complex formation: ΔΔTS~vib~ = \[TS~vib~{I~x~}~E~ − TS~vib~{I~x~}\] − \[TS~vib~{I~ref~}~E~ − TS~vib~{I~ref~}\]; ^f^ ΔΔG~com~ is the overall relative GFE change of E-I~x~ complex formation: ΔΔG~com~ ≈ ΔΔH~MM~ + ΔΔG~sol~ − ΔΔTS~vib~; ^g^ IC~50~^exp^ is the experimental half-maximal inhibition concentration of InhA obtained from ref. \[[@B23-ijms-20-04730]\]; ^h^ ratio of predicted and experimental half-maximal inhibition concentrations *p*IC~50~^pre^/*p*IC~50~^exp^ (*p*IC~50~^pre^ = −log~10~IC~50~^pre^) was predicted from computed ΔΔG~com~ using the regression equation for InhA shown in [Table 3](#ijms-20-04730-t003){ref-type="table"}, B.

ijms-20-04730-t003_Table 3

###### 

Analysis of computed binding affinities ∆∆G~com~, its enthalpic component ∆∆H~MM~, and experimental half-maximal inhibitory concentrations pIC~50~^exp^ = −log~10~IC~50~^exp^ of BHMBs towards *Mt*InhA \[[@B23-ijms-20-04730]\].

  Statistical Data of Linear Regression                          \(A\)      \(B\)
  -------------------------------------------------------------- ---------- --------
  *p*IC~50~^exp^ = −0.2465 × ∆∆H~MM~ + 7.9554 (A)                           
  *p*IC~50~^exp^ = −0.2370 × ∆∆G~com~ + 7.8783 (B)                          
  Number of compounds n                                          19         19
  Squared correlation coefficient of regression R^2^             0.94       0.97
  LOO cross-validated squared correlation coefficient R^2^~xv~   0.92       0.95
  Standard error of regression σ                                 0.178      0.135
  Statistical significance of regression, Fisher F-test          274.92     493.24
  Level of statistical significance α                            \>95 %     \>95 %
  Range of activities IC~50~^exp^ \[nM\]                         20--5930   

ijms-20-04730-t004_Table 4

###### 

Parameters of 10 generated PH4 pharmacophoric hypotheses for InhA inhibitor after Cat-Scramble validation procedure (49 scrambled runs for each hypothesis at the selected level of confidence of 98%).

  Hypothesis   RMSD ^a^   R^2\ b^   Total Costs ^c^   Costs Difference ^d^   Closest Random ^e^
  ------------ ---------- --------- ----------------- ---------------------- --------------------
  Hypo1        1.610      0.97      70.1              458.1                  147.15
  Hypo2        1.973      0.96      82.6              445.6                  155.68
  Hypo3        2.281      0.95      94.8              433.4                  183.64
  Hypo4        2.673      0.93      114.3             413.9                  201.42
  Hypo5        2.751      0.92      118.9             409.3                  205.69
  Hypo6        2.916      0.91      126.3             401.9                  213.65
  Hypo7        3.396      0.88      155.5             372.8                  214.63
  Hypo8        3.586      0.87      169.1             359.2                  241.58
  Hypo9        3.709      0.86      177.2             351.1                  247.34
  Hypo10       3.809      0.85      184.7             343.5                  260.41

^a^ root mean square deviation; ^b^ squared correlation coefficient; ^c^ overall cost parameter of the PH4 pharmacophore; ^d^ cost difference between Null cost and hypothesis total cost; ^e^ lowest cost from 49 scrambled runs at a selected level of confidence of 98%. The Fixed Cost = 45.4 with RMSD = 0, the Null Cost = 528.2 with RMSD = 7.215 and the Configuration cost = 10.63.

ijms-20-04730-t005_Table 5

###### 

R~1~- and R~2~-groups (fragments, building blocks, substituents) used in the design of the initial diversity virtual combinatorial library of benzamides.

![](ijms-20-04730-i028)

  R-groups ^a^                                                                                                                        
  -------------- ---------------------------------------------------- ----- --------------------------------------------------- ----- ---------------------------------------------------
  1              Me                                                   2     1-ClMe                                              3     Et
  4              1-F-Et                                               5     propyl                                              6     1-Brpropyl
  7              Me-thiol                                             8     1-BrMe                                              9     1-ClEt
  10             1-F-propyl                                           11    butyl                                               12    1-F-Me
  13             1-BrEt                                               14    1-Clpropyl                                          15    1-F-butyl
  16             1-Clbutyl                                            17    1-F-pentyl                                          18    hexyl
  19             1-Brhexyl                                            20    isopentyl                                           21    6,6-diMeheptyl
  22             6-diMe-heptyl                                        23    3,3-diMe-butyl                                      24    3-Mepentyl
  25             6-Meoctyl                                            26    3-Etpentyl                                          27    Me-C~3~H~5~
  28             Butyl-C~3~H~5~                                       29    Me-C~4~H~7~                                         30    Butyl-C~4~H~7~
  31             Me-C~5~H~9~                                          32    Butyl-C~5~H~9~                                      33    Me-C~6~H~11~
  34             Butyl-C~6~H~11~                                      35    cycloprop-2-en-1-yl                                 36    Thiophen-2-yl
  37             Thiophen-3-yl                                        38    Furan-2-yl                                          39    5-Me-thiophen-2-yl
  40             3,4,5-triMe-thiophen-2-yl                            41    Thiophen-2-ylMe                                     42    furan-3-ylMe
  43             3-Me-thiophen-2-yl                                   44    3,5-diMe-thiophen-2-yl                              45    Furan-2-ylMe
  46             2-(thiophen-2-yl)Et                                  47    4-Me-thiophen-2-yl                                  48    4,5-diMe-thiophen-2-yl
  49             2-(furan-2-yl)Et                                     50    Thiophen-3-ylMe                                     51    Ph
  52             4-ClPh                                               53    4-F-Ph                                              54    4-BrPh
  55             p-tolyl                                              56    3-F-Ph                                              57    3-ClPh
  58             3-BrPh                                               59    m-tolyl                                             60    2-F-Ph
  61             2-ClPh                                               62    2-BrPh                                              63    o-tolyl
  64             4-OHPh                                               65    4-MeOPh                                             66    4-OH-Bn
  67             4-MeO-Bn                                             68    -Bn                                                 69    4-F-Bn
  70             4-Cl-Bn                                              71    4-Br-Bn                                             72    4-Me-Bn
  73             3,5-diMe-Bn                                          74    4-((1H-imidazol-2-yl)Me)-Bn                         75    aminoMe
  76             diClMe                                               77    2-(1H-imidazol-2-yl)Et                              78    2-Clpropyl
  79             3-Br-2-(thiazol-2-yl)propyl                          80    (Furan-3-ylMe)thio                                  81    diBrMe
  82             2-amino-2-ClEt                                       83    3,3-diBr-3-F-propyl                                 84    4-(pyridin-3-yl)butyl
  85             F-Me-Cl                                              86    2-(1,3,4-thiadiazol-2-yl)Et                         87    2-Br-2-(1,3,4-thiadiazol-2-yl)Et
  88             1-Br-3-Clpropyl                                      89    4-(1H-imidazol-2-yl)butyl                           90    4-Cl-3-OHbutyl
  91             3-((F-Me)amino)propyl                                92    4-OHhexyl                                           93    5-amino-6-Brhexyl
  94             4-iodo-3-Mebutyl                                     95    3-(neopentylamino)propyl                            96    5-(Meamino)pentyl
  97             2-Me-3,3-diMebutyl                                   98    4-Cl-3-Mepentyl                                     99    6-aminooctyl
  100            6-amino-3-Et-4-Meoctyl                               101   cycloprop-2-en-1-ylMe                               102   (4-Mecyclohexyl)Me
  103            Me-cyclohexyl                                        104   Me-cyclopentyl                                      105   -Bn
  106            4-Me-Bn                                              107   4-MeO-Bn                                            108   4-Et-Bn
  109            4-Cl-Bn                                              110   4-F-Bn                                              111   4-(F-Me)-Bn
  112            3,4-diF-Bn                                           113   3,5-diF-Bn                                          114   2-Cl-4-F-Bn
  115            4-Cl-2-F-Bn                                          116   4-Br-5-Et-2-F-Bn                                    117   2-F-4-Me-Bn
  118            2,6-diF-Bn                                           119   2,4-diF-Bn                                          120   2,4,6-triF-Bn
  121            3-(CF~3~)pyridin-2-yl                                122   2-(CF~3~)pyridin-3-yl                               123   3-(CF~3~)pyridin-4-yl
  124            3-Br-pyridin-2-yl                                    125   4-MeO-3-(CF~3~)pyridin-2-yl                         126   4-(CF~3~)pyridin-3-yl
  127            2-(CF~3~)Ph                                          128   Ph                                                  129   EtO
  130            2-(6-Et-3,6-dihydro-2H-pyran-2-yl)EtO                131   4-(5-F-1H-pyrazol-1-yl)Ph                           132   4-(4-F-1H-pyrazol-1-yl)Ph
  133            4-(3-F-1H-pyrazol-1-yl)Ph                            134   4-(3,4-diF-1H-pyrazol-1-yl)Ph                       135   4-(3,4,5-triF-1H-pyrazol-1-yl)Ph
  136            4-(4,5-diF-1H-pyrazol-1-yl)Ph                        137   4-(3,5-diF-1H-pyrazol-1-yl)Ph                       138   4-(3-Br-1H-pyrazol-1-yl)Ph
  139            4-(4-Br-1H-pyrazol-1-yl)Ph                           140   4-(5-Br-1H-pyrazol-1-yl)Ph                          141   4-(4,5-diBr-1H-pyrazol-1-yl)Ph
  142            4-(3,4-diBr-1H-pyrazol-1-yl)Ph                       143   4-(3,5-diBr-1H-pyrazol-1-yl)Ph                      144   4-(3,4,5-triBr-1H-pyrazol-1-yl)Ph
  145            4-(5-Me-1H-pyrazol-1-yl)Ph                           146   4-(4-Me-1H-pyrazol-1-yl)Ph                          147   4-(3-Me-1H-pyrazol-1-yl)Ph
  148            4-(3,4-diMe-1H-pyrazol-1-yl)Ph                       149   4-(4,5-diMe-1H-pyrazol-1-yl)Ph                      150   4-(3,5-diMe-1H-pyrazol-1-yl)Ph
  151            4-(3,4,5-triMe-1H-pyrazol-1-yl)Ph                    152   4-(3-iodo-1H-pyrazol-1-yl)Ph                        153   4-(4-iodo-1H-pyrazol-1-yl)Ph
  154            4-(5-iodo-1H-pyrazol-1-yl)Ph                         155   4-(4,5-diI-1H-pyrazol-1-yl)Ph                       156   4-(3,4-diI-1H-pyrazol-1-yl)Ph
  157            4-(3,4,5-triiodo-1H-pyrazol-1-yl)Ph                  158   4-(3,5-diI-1H-pyrazol-1-yl)Ph                       159   4-(3-Cl-1H-pyrazol-1-yl)Ph
  160            4-(4-Cl-1H-pyrazol-1-yl)Ph                           161   4-(5-Cl-1H-pyrazol-1-yl)Ph                          162   4-(4,5-diCl-1H-pyrazol-1-yl)Ph
  163            4-(3,5-diCl-1H-pyrazol-1-yl)Ph                       164   4-(3,4-diCl-1H-pyrazol-1-yl)Ph                      165   4-(3,4,5-triCl-1H-pyrazol-1-yl)Ph
  166            4-(3-amino-1H-pyrazol-1-yl)Ph                        167   4-(4-amino-1H-pyrazol-1-yl)Ph                       168   4-(5-amino-1H-pyrazol-1-yl)Ph
  169            4-(4,5-diamino-1H-pyrazol-1-yl)Ph                    170   4-(3,5-diamino-1H-pyrazol-1-yl)Ph                   171   4-(3,4-diamino-1H-pyrazol-1-yl)Ph
  172            4-(3,4,5-triamino-1H-pyrazol-1-yl)Ph                 173   4-(3-Me-1H-pyrazol-1-yl)Ph                          174   4-(4-Me-1H-pyrazol-1-yl)Ph
  175            4-(5-Me-1H-pyrazol-1-yl)Ph                           176   4-(4,5-diMe-1H-pyrazol-1-yl)Ph                      177   4-(3,5-diMe-1H-pyrazol-1-yl)Ph
  178            4-(3,4-diMe-1H-pyrazol-1-yl)Ph                       179   4-(3,4,5-triMe-1H-pyrazol-1-yl)Ph                   180   4-(5-Et-1H-pyrazol-1-yl)Ph
  181            4-(4-Et-1H-pyrazol-1-yl)Ph                           182   4-(5-Et-4-Me-1H-pyrazol-1-yl)Ph                     183   4-(5-Et-3,4-diMe-1H-pyrazol-1-yl)Ph
  184            4-(5-(Me-thio)-1H-pyrazol-1-yl)Ph                    185   4-(4-Me-5-(Me-thio)-1H-pyrazol-1-yl)Ph              186   4-(4,5-bis(Me-thio)-1H-pyrazol-1-yl)Ph
  187            4-(3-Me-4,5-bis(Me-thio)-1H-pyrazol-1-yl)Ph          188   4-(5-(aminothio)-1H-pyrazol-1-yl)Ph                 189   4-(4-(aminothio)-1H-pyrazol-1-yl)Ph
  190            4-(4-(aminothio)-5-ME-1H-pyrazol-1-yl)Ph             191   4-(4,5-bis(aminothio)-1H-pyrazol-1-yl)Ph            192   \[1,1′-biPh\]-4-yl
  193            4-(5H-tetrazol-5-yl)Ph                               194   4-(1H-imidazol-1-yl)Ph                              195   4-(1H-1,2,4-triazol-1-yl)Ph
  196            4-(1H-tetrazol-1-yl)Ph                               197   4-(thiophen-2-yl)Ph                                 198   4-(pyridin-2-yl)Ph
  199            4-(pyrazin-2-yl)Ph                                   200   4-(pyrimidin-2-yl)Ph                                201   4-(pyridazin-3-yl)Ph
  202            4-(piperazin-1-yl)Ph                                 203   3H-indol-2-yl                                       204   7H-purin-8-yl
  205            1,8a-dihydroindolizin-2-yl                           206   isoquinolin-6-yl                                    207   quinolin-6-yl
  208            cyclopenta-2,4-dienecarbonyl                         209   2-Mecyclopenta-2,4-dienecarbonyl                    210   2-F-cyclopenta-2,4-dienecarbonyl
  211            2-aminocyclopenta-2,4-dienecarbonyl                  212   2-Mecyclopenta-2,4-dienecarbonyl                    213   3-Mecyclopenta-2,4-dienecarbonyl
  214            2,3-diMecyclopenta-2,4-dienecarbonyl                 215   2-Clcyclopenta-2,4-dienecarbonyl                    216   3-Clcyclopenta-2,4-dienecarbonyl
  217            2,3-diClcyclopenta-2,4-dienecarbonyl                 218   3-Brcyclopenta-2,4-dienecarbonyl                    219   2-Brcyclopenta-2,4-dienecarbonyl
  220            2,3-diBrcyclopenta-2,4-dienecarbonyl                 221   2-iodocyclopenta-2,4-dienecarbonyl                  222   3-iodocyclopenta-2,4-dienecarbonyl
  223            2,3-diIcyclopenta-2,4-dienecarbonyl                  224   amino(cyclopenta-2,4-dien-1-yl)Me                   225   amino(2-F-cyclopenta-2,4-dien-1-yl)Me
  226            NH~2~(2,3-diF-cyclopenta-2,4-dien-1-yl)Me            227   NH~2~(2-Mecyclopenta-2,4-dien-1-yl)Me               228   HN(2,3-diMecyclopenta-2,4-dien-1-yl)Me
  229            (2,3-diMecyclopenta-2,4-dien-1-yl)(CH~3~NHMe         230   (CH~3~NH)(2-Mecyclo-penta-2,4-dien-1-yl)Me          231   (CH~3~NH)(3-Mecyclo-penta-2,4-dien-1-yl)Me
  232            (3-F-cyclopenta-2,4-dien-1-yl)(CH~3~NH)Me            233   (2-F-cyclopenta-2,4-dien-1-yl)(CH~3~NH)Me           234   (2,3-diF-cyclopenta-2,4-dien-1-yl)(CH~3~NH)Me
  235            (2,3-diMecyclopenta-2,4-dien-1-yl)(FNH)Me            236   FNH(2-Mecyclopenta-2,4-dien-1-yl)Me                 237   FNH(3-Mecyclopenta-2,4-dien-1-yl)Me
  238            F-amino(3-F-cyclopenta-2,4-dien-1-yl)Me              239   (2,3-diF-cyclopenta-2,4-dien-1-yl)(FNH)Me           240   (2,3-diClcyclopenta-2,4-dien-1-yl)(FNH)Me
  241            (2-Clcyclopenta-2,4-dien-1-yl)(FNH)Me                242   (3-Clcyclopenta-2,4-dien-1-yl)(FNH)Me               243   (3-Brcyclopenta-2,4-dien-1-yl)(F-amino)Me
  244            (2,3-diBrcyclopenta-2,4-dien-1-yl)(FNH)Me            245   (2-Brcyclopenta-2,4-dien-1-yl)(FNH)Me               246   NH~2~(2-carbamoylcyclopenta-2,4-dien-1-yl)Me
  247            NH~2~(3-carbamoylcyclopenta-2,4-dien-1-yl)Me         248   NH~2~(2-carbamoyl-3-F-cyclopenta-2,4-dien-1-yl)Me   249   NH~2~(2-carbamoyl-3-Clcyclopenta-2,4-dien-1-yl)Me
  250            NH~2~(3-NH-2-carbamoylcyclo penta-2,4-dien-1-yl)Me   251   2-carbamoylPh-HCOO^--^                              252   3-carbamoylPh-HCOO^--^
  253            4-carbamoylPh-HCOO^--^                               254   2-MePh-HCOO^--^                                     255   3-MePh-HCOO^--^
  256            3-MePh-HCOO^--^                                      257   2,3-diMePh-HCOO^--^                                 258   (2-carbamoylPh)(imino)Me
  259            imino(Ph)Me                                          260   3-carbamoylPh(imino)Me                              261   4-carbamoylPh(imino)Me
  262            imino(2-MePh)Me                                      263   2,3-diMePh(imino)Me                                 264   imino(3-MePh)Me
  265            imino(4-MePh)Me                                      266   (F-imino)(2-F-Ph)Me                                 267   F-imino(3-F-Ph)Me
  268            (3-BrPh)(F-imino)Me                                  269   (2-BrPh)(F-imino)Me                                 270   (2-ClPh)(F-imino)Me
  271            (3-ClPh)(F-imino)Me                                  272   Brimino(3-ClPh)Me                                   273   Brimino(3-BrPh)Me
  274            Cl-imino(3-ClPh)Me                                   275   Cl-imino(2-ClPh)Me                                  276   imino(o-tolyl)Me
  277            imino(2-(CF~3~)Ph)Me                                 278   imino(3-(CF~3~)Ph)Me                                279   3-formylbenzamide
  280            2-formylbenzamide                                    281   4-formylbenzamide                                   282   -Bz-2-Me
  283            -Bz-2,3-diMe                                         284   -Bz-3-Me                                            285   -Bz-4-Me
  286            -Bz-2-Me                                             287   -Bz-2-(CF~3~)                                       288   -Bz-3-(CF~3~)
  289            -Bz-2-F-                                             290   NH~2~(3-Br-2-carbamoylcyclopenta-2,4-dien-1-yl)Me   291   Carbamoyl
  292            4-Cl-1H-pyrazol-1-yl                                 293   4,5-diCl-1H-pyrazol-1-yl                            294   5-Cl-1H-pyrazol-1-yl
  295            3-Cl-1H-pyrazol-1-yl                                 296   3-Br-1H-pyrazol-1-yl                                297   4-Br-1H-pyrazol-1-yl
  298            5-Br-1H-pyrazol-1-yl                                 299   4,5-diBr-1H-pyrazol-1-yl                            300   3,4,5-triBr-1H-pyrazol-1-yl
  301            4-Me-1H-pyrazol-1-yl                                 302   4,5-diMe-1H-pyrazol-1-yl                            303   5-Me-1H-pyrazol-1-yl
  304            5-iodo-1H-pyrazol-1-yl                               305   4-iodo-1H-pyrazol-1-yl                              306   3-iodo-1H-pyrazol-1-yl
  307            3,4-diI-1H-pyrazol-1-yl                              308   3,4,5-triiodo-1H-pyrazol-1-yl                       309   3,4,5-triF-1H-pyrazol-1-yl
  310            3-F-1H-pyrazol-1-yl                                  311   3,4-diF-1H-pyrazol-1-yl                             312   4-F-1H-pyrazol-1-yl
  313            5-F-1H-pyrazol-1-yl                                  314   3-NH~2~-1H-pyrazol-1-yl                             315   4-amino-1H-pyrazol-1-yl
  316            5-amino-1H-pyrazol-1-yl                              317   5-Me-1H-pyrazol-1-yl                                318   5-Et-1H-pyrazol-1-yl
  319            4-Me-1H-pyrazol-1-yl                                 320   4,5-diMe-1H-pyrazol-1-yl                            321   5-(Me-Me)-1H-pyrazol-1-yl
  322            4-Me-5-(Me-Me)-1H-pyrazol-1-yl                       323   5-(H~2~N-thio)-4-Me-1H-pyrazol-1-yl                 324   4,5-bis(aminothio)-1H-pyrazol-1-yl
  325            4,5-bis(H~2~N-thio)-3-Me-1H-pyrazol-1-yl             326   5-Et-4-Me-1H-pyrazol-1-yl                           327   pyridazin-3-yl
  328            pyridazin-4-yl                                       329   pyrimidin-4-yl                                      330   1,3,5-triazin-2-yl
  331            pyrimidin-2-yl                                       332   pyrazin-2-yl                                        333   Cyclohexyl
  334            piperidin-1-yl                                       335   tetrahydropyridazin-1(2H)-yl                        336   piperazin-1-yl
  337            1,2,4-triazinan-1-yl                                 338   2-(thiazol-2-yl)butyl                               339   2-(thiazol-2-yl)pentyl

^a^ All fragments were used for substitutions in the R~1~ and R~2~ positions.
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###### 

GFE and their components for the top scoring 90 virtual BHMB analogs. The analog numbering concatenates the index of each substituent R~1~ to R~2~ with the substituent numbers taken from [Table 5](#ijms-20-04730-t005){ref-type="table"} except for hydrogen which is directly specified by the letter H.
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  Designed Analogs   M~w~ ^a^ \[g⋅mol^−1^\]   ΔΔH~MM~ ^b^ \[kcal⋅mol^−1^\]   ΔΔG~sol~ ^c^ \[kcal⋅mol^−1^\]   ΔΔTS~vib~ ^d^ \[kcal⋅mol^−1^\]   ΔΔG~com~ ^e^ \[kcal⋅mol^−1^\]   IC~50~^pre\ f^ \[nM\]   
  ------------------ ------------------------ ------------------------------ ------------------------------- -------------------------------- ------------------------------- ----------------------- --------
  N                  BHMB1                    385                            0                               0                                0                               0                       20 ^g^
  1                  32--218                  389                            −21.96                          14.78                            0.15                            −7.33                   0.24
  2                  39--95                   359                            21.7                            2.26                             1.98                            21.99                   1996
  3                  40--232                  439                            −1.72                           5.01                             −1.65                           4.94                    200
  4                  40--234                  405                            −10.02                          2.93                             0.99                            −8.08                   0.16
  5                  41--93                   409                            −11.28                          3.31                             2.16                            −10.14                  0.052
  6                  42--207                  342                            −7.22                           6.24                             −4.45                           3.47                    90
  7                  47--235                  421                            −5.66                           3.16                             −5.73                           3.24                    80
  8                  54--282                  505                            −3.55                           6.63                             −3.02                           6.1                     370
  9                  65--235                  413                            −5.71                           3.01                             1.99                            −4.69                   1
  10                 67--67                   375                            −8.72                           3.21                             0.32                            −5.83                   0.55
  11                 67--212                  505                            0.56                            2.82                             −2.2                            5.59                    280
  12                 67--215                  599                            3.45                            3.22                             −2.52                           9.18                    1990
  13                 70--241                  430                            −13.98                          14.15                            −1.02                           1.18                    30
  14                 72--232                  401                            −10.09                          4.74                             −0.7                            −4.65                   1
  15                 79--9                    402                            −12.2                           15.92                            −2.82                           6.54                    470
  16                 79--92                   439                            −13.99                          6.17                             3.15                            −10.97                  0.033
  17                 79--215                  683                            −4.32                           2.82                             −5.06                           3.56                    94
  18                 79--338                  375                            −12.46                          5.35                             3.19                            −10.3                   0.047
  19                 79--339                  389                            −13.64                          5                                2.01                            −10.65                  0.039
  20                 86--233                  393                            −14.09                          17.65                            −2.46                           6.02                    350
  21                 87--24                   410                            −8.64                           4.95                             1.59                            −5.28                   0.74
  22                 87--122                  480                            −9.46                           4.77                             0.39                            −5.07                   0.83
  23                 87--205                  450                            −13.78                          17.73                            −4.81                           8.75                    1570
  24                 87--208                  453                            −7.19                           3.56                             −4.64                           1.01                    20
  25                 92--169                  406                            −14.2                           14.73                            5.02                            −4.48                   2
  26                 95--215                  606                            −6.76                           1.94                             −2.28                           −2.53                   4
  27                 106--215                 605                            −6.81                           2.61                             −6.96                           2.76                    60
  28                 106--233                 407                            −7.12                           5.75                             −3.77                           2.4                     50
  29                 106--241                 432                            −2.77                           6.09                             −2.2                            5.51                    270
  30                 111--95                  389                            9.21                            −0.51                            0.18                            8.52                    1380
  31                 112--208                 388                            2.68                            0.15                             −2.26                           5.09                    210
  32                 114--232                 460                            −11.36                          15.18                            −4.36                           8.18                    1150
  33                 118--84                  443                            −6.36                           4.46                             −0.67                           −1.23                   7
  34                 118--235                 500                            −5.5                            1.49                             −3.13                           −0.89                   9
  35                 122--57                  400                            −12.27                          15.46                            1.16                            2.03                    40
  36                 122--88                  445                            −11.79                          16.54                            −0.93                           5.68                    290
  37                 122--92                  390                            −18.45                          16.69                            7.09                            −8.85                   0.1
  38                 122--282                 504                            −6.19                           12.29                            2.79                            3.31                    81
  39                 128--232                 493                            −19.75                          17.06                            −6.07                           3.38                    83
  40                 138--65                  416                            −18.69                          16.51                            −0.24                           −1.94                   5
  41                 147--282                 744                            −16.78                          13.56                            −7.11                           3.89                    110
  42                 158--209                 453                            −20.41                          19.64                            −2.82                           2.05                    41
  43                 166--92                  393                            −14.08                          7.1                              1.14                            −8.12                   0.15
  44                 169--232                 485                            −18.91                          17.42                            −5.38                           3.9                     113
  45                 172--235                 495                            −23.56                          16.58                            −4.17                           −2.81                   3
  46                 174--214                 537                            −15.39                          17.46                            −0.99                           3.06                    71
  47                 174--311                 399                            −20.87                          18.65                            −2.04                           −0.18                   12
  48                 177--282                 571                            −15.7                           15.55                            −7.49                           7.34                    725
  49                 178--233                 515                            −22.75                          17.89                            −5.82                           0.96                    23
  50                 185--282                 494                            −10.48                          15.12                            −4.02                           8.66                    1514
  51                 201--15                  315                            −15.79                          15.32                            3.25                            −3.72                   2
  52                 214--233                 499                            3.45                            2.69                             −2.89                           9.03                    1820
  53                 220--99                  420                            −7.16                           3.71                             5.22                            −8.66                   0.11
  54                 225--233                 424                            −7.4                            15.23                            −1.23                           9.05                    1863
  55                 232--276                 451                            −19                             17.57                            −0.81                           −0.63                   2
  56                 234--99                  408                            −8.67                           3.96                             4.31                            −9.02                   0.09
  57                 234--234                 426                            −5.74                           17.27                            2.21                            9.32                    2138
  58                 238--25                  398                            −5.51                           5.21                             8.81                            −9.11                   0.09
  59                 240--84                  423                            −15.36                          16.82                            −0.29                           1.74                    34
  60                 241--63                  396                            −7.77                           19.23                            5.04                            6.42                    437
  61                 244--99                  426                            −9.46                           6.19                             0.9                             −4.17                   2
  62                 245--43                  394                            −14.47                          19.17                            −0.26                           4.96                    200
  63                 245--174                 483                            −19.31                          16.99                            −4.81                           2.48                    52
  64                 261--212                 585                            −4.95                           4.87                             −8.29                           8.21                    1175
  65                 266--210                 478                            −3.42                           4.54                             −5.75                           6.88                    563
  66                 269--215                 650                            −4.2                            3.14                             −5.61                           4.54                    159
  67                 269--233                 452                            −12.9                           5.61                             −3.64                           −3.65                   2
  68                 269--236                 575                            −6.69                           4.6                              −5.62                           3.53                    92
  69                 270--232                 486                            −8.35                           5.48                             −6.4                            3.53                    92
  70                 279--214                 525                            −5.1                            −0.63                            −4.71                           −1.02                   8
  71                 279--282                 522                            −2.8                            5.06                             −4.06                           6.32                    417
  72                 282--26                  448                            −13.63                          18.31                            5.63                            −0.95                   8
  73                 282--280                 522                            −10.39                          2.59                             −3.51                           −4.3                    2
  74                 297--28                  423                            −5.81                           3.84                             2.05                            −4.01                   2
  75                 307--99                  343                            −7.43                           6.73                             3.3                             −4.01                   2
  76                 308--25                  342                            −6.7                            6.12                             3.74                            −4.32                   2
  77                 310--99                  357                            −10.86                          4.79                             2.67                            −8.74                   0.11
  78                 310--74                  525                            3.9                             1.65                             −3.08                           8.63                    1479
  79                 310--209                 390                            2.99                            −0.1                             −3.93                           6.82                    550
  80                 310--289                 374                            2.6                             −0.5                             −1.85                           4.1                     124
  81                 313--278                 365                            −20.4                           18.73                            −0.79                           −0.88                   9
  82                 316--150                 689                            −17.61                          14.38                            −8.08                           4.85                    187
  83                 317--98                  446                            −11.26                          17.19                            1.24                            4.69                    170
  84                 318--79                  447                            −10.86                          9.09                             −1.71                           −0.07                   13
  85                 318--89                  365                            −4.96                           3.62                             1.15                            −2.48                   4
  86                 318--198                 370                            0.06                            4.96                             1.85                            3.17                    75
  87                 318--207                 370                            −11.32                          5.52                             1.37                            −7.17                   0.26
  88                 318--212                 493                            −9.55                           3.93                             −1.59                           −4.02                   2
  89                 320--19                  376                            3.36                            3.01                             4.03                            2.34                    48
  90                 321--25                  339                            −1.01                           2.16                             4.2                             −3.05                   3

^a^ M~w~ is molar mass of inhibitor; ^b^ ΔΔH~MM~ is the relative enthalpic contribution to the GFE change of the InhA-BHMB complex formation ΔΔG~com~ (for details see footnote pf [Table 2](#ijms-20-04730-t002){ref-type="table"}); ^c^ ΔΔG~sol~ is the relative solvation GFE contribution to ΔΔG~com~; ^d^ ΔΔTS~vib~ is the relative (vibrational) entropic contribution to ΔΔG~com~; ^e^ ΔΔG~com~ is the relative Gibbs free energy change related to the enzyme--inhibitor InhA-BHMB complex formation ΔΔG~com~ ≅ ΔΔH~MM~ + ΔΔG~sol~ − ΔΔTS~vib~; ^f^ IC~50~^pre^ is the predicted inhibition potency towards *Mt*InhA calculated from ΔΔG~com~ using correlation Equation B, [Table 3](#ijms-20-04730-t003){ref-type="table"}; ^g^ IC~50~^exp^ \[[@B19-ijms-20-04730]\] is given for the reference inhibitor BHMB1 instead of the IC~50~^pre^.

ijms-20-04730-t007_Table 7

###### 

ADME-related properties of the best designed BHMB analogs and known antituberculotic agents either in clinical use or currently undergoing clinical testing computed by QikProp \[[@B33-ijms-20-04730]\].

  BHMBx ^a^      \#stars ^b^   M~w~ ^c^ \[g.mol^−1^\]   S~mol~ ^d^ \[Å^2^\]   S~mol,hfo~ ^e^ \[Å^2^\]   V~mol~ ^f^ \[Å^3^\]   RotB ^g^   HB~don~ ^h^   HB~acc~ ^i^   logP~o/w~ ^j^   logS~wat~ ^k^   logK~HSA~ ^l^   logB/B ^m^   BIP~caco~ ^n^ \[nm.s^−1^\]   \#meta ^o^   IC~50~^pre^ \[nM\]   HOA^q^   %HOA^r^
  -------------- ------------- ------------------------ --------------------- ------------------------- --------------------- ---------- ------------- ------------- --------------- --------------- --------------- ------------ ---------------------------- ------------ -------------------- -------- ---------
  32--218        0             389                      760                   380.1                     1340                  10         3             3.5           5.1             −5.8            0.94            −0.49        320.6                        4            0.24                 3        89
  40--234        1             405                      703                   285.9                     1253                  6          2             3.5           5.8             −7.2            1               −0.11        2551.9                       8            0.16                 1        100
  41--93         0             409                      691                   230.2                     1218                  11         3             3.5           4.5             −4.6            0.57            −0.42        301.4                        5            0.05                 3        100
  67--67         1             375                      716                   305.9                     1278                  8          1             4             5.8             −6.5            0.98            −0.42        3493.1                       4            0.55                 1        100
  79--92         0             439                      737                   323.6                     1306                  12         2             5.7           4.8             −5.9            0.48            −1.01        1105.1                       4            0.033                3        100
  79--338        0             375                      680                   367.1                     1268                  12         2             5.7           4.5             −4.7            0.41            −0.83        1688.3                       4            0.047                3        100
  79--339        0             389                      760                   431.0                     1368                  13         2             5.7           5               −5.9            0.6             −1.15        1371.3                       4            0.039                3        100
  87--24         0             410                      701                   332.5                     1226                  9          1             4.5           4.8             −6.3            0.68            −0.96        882.4                        3            0.74                 1        100
  87--122        0             480                      762                   347.2                     1363                  10         1             6.95          5               −6.3            0.5             −0.62        1884.2                       6            0.83                 1        100
  122--92        0             390                      808                   522.4                     1430                  13         2             7.6           4.5             −5.9            0.39            −1.28        1347.2                       6            0.10                 3        100
  166--92        0             393                      739                   244.7                     1324                  10         4             5.7           3.9             −5.5            0.44            −1.83        254.9                        3            0.15                 3        92
  234--99        0             408                      730                   318.4                     1343                  13         4             4.5           4.5             −4.4            0.56            −0.79        180.9                        5            0.09                 3        93
  310--74        1             525                      797                   239.5                     1419                  8          2             5             6               −7.8            1.07            −0.81        1168.4                       3            0.11                 1        91
  318--207       0             370                      683                   215.9                     1198                  6          1             5.5           4.3             −6              0.53            −0.73        1021.2                       3            0.26                 3        100
  Rifampin       1             137.1                    314                   0.0                       480 \*                2          3             4.5           −0.7            0               −0.8            −0.8         267.5                        2            −                    2        67
  Isoniazid      4             123.1 \*                 300                   0.0                       443 \*                1          2             5             −0.6            −0.5            −0.8            −0.7         298.4                        4            −                    2        67
  Ethambutol     2             204.3                    476                   395.8                     806                   11         4             6.4           −0.2            0.6             −0.8            0.0          107.8                        4            −                    2        62
  Pyrazinamide   10            823.0 \*                 1090 \*               850.0 \*                  2300 \*               25 \*      6             20.3 \*       3.0             −3.1            −0.3            −2.7         38.2                         11^\*^       −                    1        34
  Gatifloxacin   0             375.4                    598                   355.7                     1093                  2          1             6.8           0.5             −4.0            0               −0.6         17.0                         1            −                    2        52
  Moxifloxacin   0             401.4                    642                   395.6                     1168                  2          1             6.8           1.0             −4.7            0.2             −0.6         20.9                         1            −                    2        56
  Rifapentine    10            877.0 \*                 1025 \*               844.9 \*                  2333 \*               24 \*      6             20.9 \*       3.6             −2.2            −0.2            −1.5         224.0                        13^\*^       −                    1        51
  Bedaquiline    4             555.5                    787                   213.7                     1532                  9          1             3.8           7.6 \*          −6.9            1.7             0.4          1562.2                       5            −                    1        100
  Delamanid      2             534.5                    796                   284.4                     1470                  7          0             6.0           5.8             −7.6            1.0             −1.0         590.9                        2            −                    1        85
  Linezolid      0             337.4                    555                   337.2                     996                   2          1             8.7           0.6             −2.0            −0.7            −0.5         507.0                        2            −                    3        79
  Sutezolid      1             353.4                    594                   330.6                     1047                  2          1             7.5           1.3             −3.4            −0.4            −0.4         449.3                        0            −                    3        82
  Ofloxacin      1             361.4                    581                   337.0                     1044                  1          0             7.3           −0.4            −2.8            −0.5            −0.4         25.9                         1            −                    2        50
  Amikacin       14            585.6                    739                   350.3                     1500                  22^\*^     17 \*         26.9 \*       −7.9^\*^        −0.2            −2.1            −3.5         0                            14^\*^       −                    1        0
  Kanamycin      10            484.5                    656                   258.9                     1291                  17^\*^     15 \*         22.7 \*       −6.7 \*         2.0             −1.4            −3.1         0                            12^\*^       −                    1        0
  Imipenem       0             299.3                    487                   259.1                     880                   8          3             7.2           1.0             −1.8            −0.7            −1.4         35.0                         3            −                    3        61
  Amoxicillin    2             365.4                    561                   164.6                     1033                  6          4.25          8.0           −2.5            −0.8            −1.1            −1.5         1.0                          5            −                    1        12
  Clavulanate    0             199.2                    397                   184.6                     630                   4          2             6.5           −0.8            0.3             −1.3            −1.3         13.3                         2            −                    2        42

^a^ designed BHMB analogs and known antituberculotic agents, [Table 6](#ijms-20-04730-t006){ref-type="table"}; ^b^ drug likeness, number of property descriptors (24 out of the full list of 49 descriptors of QikProp, ver. 3.7, release 14) that fall outside of the range of values for 95% of known drugs; ^c^ molar mass in \[g.mol-1\] (range for 95% of drugs: 130--725 g.mol^−1^) \[[@B33-ijms-20-04730]\]; ^d^ total solvent-accessible molecular surface, in \[Å2\] (probe radius 1.4 Å) (range for 95% of drugs: 300--1000 Å2); ^e^ hydrophobic portion of the solvent-accessible molecular surface, in \[Å2\] (probe radius 1.4 Å) (range for 95% of drugs: 0--750 Å2); ^f^ total volume of molecule enclosed by solvent-accessible molecular surface, in \[Å3\] (probe radius 1.4 Å) (range for 95% of drugs: 500--2000 Å3); ^g^ number of non-trivial (not CX3), non-hindered (not alkene, amide, small ring) rotatable bonds (range for 95% of drugs: 0--15); ^h^ estimated number of hydrogen bonds that would be donated by the solute to water molecules in an aqueous solution. Values are averages taken over a number of configurations, so they can assume non-integer values (range for 95% of drugs: 0.0--6.0); ^i^ estimated number of hydrogen bonds that would be accepted by the solute from water molecules in an aqueous solution. Values are averages taken over a number of configurations, so they can assume non-integer values (range for 95% of drugs: 2.0--20.0); ^j^ logarithm of partitioning coefficient between n-octanol and water phases (range for 95% of drugs: −2 to 6.5); ^k^ logarithm of predicted aqueous solubility, logS. S in \[mol·dm--3\] is the concentration of the solute in a saturated solution that is in equilibrium with the crystalline solid (range for 95% of drugs: −6.0 to 0.5); ^l^ logarithm of predicted binding constant to human serum albumin (range for 95% of drugs: −1.5 to 1.5); ^m^ logarithm of predicted brain/blood partition coefficient (range for 95% of drugs: −3.0 to 1.2); ^n^ predicted apparent Caco-2 cell membrane permeability in Boehringer-Ingelheim scale in \[nm s-1\] (range for 95% of drugs: \< 25 poor, \> 500 nm s^−1^ great); ^o^ number of likely metabolic reactions (range for 95% of drugs: 1--8); ^p^ predicted inhibition constants IC50pre. IC50pre was predicted from computed ΔΔGcom using the regression Equation B shown in [Table 3](#ijms-20-04730-t003){ref-type="table"}; ^q^ human oral absorption (1 = low, 2 = medium, 3 = high); r percentage of human oral absorption in gastrointestinal tract (\<25% = poor, \>80% = high); \* star in any column indicates that the property descriptor value of the compound falls outside the range of values for 95% of known drugs.

ijms-20-04730-t008_Table 8

###### 

GFE, its components, and predicted InhA inhibitory potencies of 24 approved drugs which contain benzamide scaffold in their molecular structure (for 2D representation see [Table 9](#ijms-20-04730-t009){ref-type="table"}).

  DrugBank Accession Number   Name ^a^                 M~w~ \[g⋅mol^−1^\]   ΔΔH~MM~ \[kcal⋅mol^−1^\]   ΔΔG~sol~ \[kcal⋅mol^−1^\]   ΔΔTS~vib~ \[kcal⋅mol^−1^\]   ΔΔG~com~ \[kcal⋅mol^−1^\]   IC~50~^pre^ \[nM\]
  --------------------------- ------------------------ -------------------- -------------------------- --------------------------- ---------------------------- --------------------------- --------------------
  DB00345                     Aminohippuric Acid       194                  10.6                       3.81                        2.03                         12.39                       11,370
  DB00391                     Sulpiride                341                  4.53                       3.59                        3.91                         4.2                         132
  DB00409                     Remoxipride              371                  11.49                      −1.65                       7.06                         2.78                        60
  DB00604                     Cisapride                465                  8.47                       −0.06                       2.97                         5.44                        258
  DB00619                     Imatinib                 493                  −3.54                      13.79                       2.56                         7.69                        879
  DB01035                     Procainamide             235                  12.97                      2.22                        6.14                         9.05                        1 847
  DB01168                     Procarbazine             221                  16.54                      1.73                        2.12                         16.15                       88,971
  DB01171                     Moclobemide              268                  −7.79                      16.78                       3.22                         5.76                        308
  DB01233                     Metoclopramide           299                  −4.54                      17.82                       6.47                         6.81                        544
  DB01393                     Bezafibrate              361                  −11.95                     18.14                       1.32                         4.87                        189
  DB06288                     Amisulpride              369                  4.91                       5.02                        6.5                          3.42                        86
  DB06421                     Declopramide             269                  −6.29                      17.29                       1.34                         9.66                        2577
  DB06422                     Tricalopride             313                  −13.62                     17.61                       4.43                         −0.44                       10
  DB06626                     Axtinib                  386                  5.04                       0.12                        −0.46                        5.62                        281.8
  DB07069                     3-Hydroxyhippuric Acid   195                  0.99                       5.78                        1.41                         5.36                        247
  DB08950                     Indoramin                347                  −2.33                      18.92                       4.19                         12.39                       11,495
  DB09018                     Bromopride               344                  −8.55                      17.12                       3.08                         5.49                        265
  DB11282                     Diethyltoluamide         191                  2.37                       2.47                        5.48                         −0.64                       9
  DB11480                     Zoalene                  225                  −0.72                      7.5                         0                            6.78                        535
  DB12518                     Raclopride               347                  −12                        18.54                       1.78                         4.77                        178
  DB13025                     Tiapride                 328                  5.98                       2.72                        4.83                         3.86                        109
  DB13273                     Sultopride               354                  −17.19                     19.7                        6.23                         −3.42                       1.7
  DB13523                     Veralipride              384                  0.93                       4.96                        4.84                         1.05                        23
  *DB15445*                   Iodohippuric Acid        305                  1.09                       6.93                        −1.76                        9.78                        2751

^a^ for definition of the individual quantities see the footnote of [Table 2](#ijms-20-04730-t002){ref-type="table"}.
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###### 

Representation for 24 approved drugs containing benzamide scaffold listed in [Table 8](#ijms-20-04730-t008){ref-type="table"}.
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